Return to the Full Article View You can republish this story for free. Click the "Copy HTML" button below. Questions? Get more details.

Watch: Explaining the Nitty-Gritty of Medicare Drug Price Negotiations — And Patients’ Potential Savings

Julie Rovner, KHN’s chief Washington correspondent, joined PBS NewsHour’s Laura Barrón-López on July 29 to discuss Senate Democrats’ proposals to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors and continue funding for enhanced premium subsidies for people buying health insurance on the Affordable Care Act’s marketplaces.

Republicans and Democrats have been at odds over allowing Medicare to negotiate drug prices since the drug benefit was passed in 2003.

The plan before the Senate would start with just 10 drugs for price negotiations in the first year, and it would not expand very much. But, Rovner notes, those could include some of the most expensive drugs, so the change could have an “outsized impact.” You can watch the conversation here.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

Some elements may be removed from this article due to republishing restrictions. If you have questions about available photos or other content, please contact NewsWeb@kff.org.